EC Number |
Inhibitors |
Structure |
---|
1.14.13.9 | (1S,2S)-2-(3,4-dichlorobenzoyl)-cyclopropane-1-carboxylic acid |
KMO inhibitor UPF 648, totally blocks KMO at 0.1 and 0.01 mM and is still highly active at 0.001 mM (81% inhibition). It reduces 3-hydroxykynurenine synthesis by 64% without affecting kynurenic acid formation. In neuron-depleted striata, UPF 648 decreases both 3-hydroxykynurenine and quinolinic acid production by 77% and 66%, respectively and also raises kynurenic acid synthesis by 27%. 0.1 mM UPF 648 blocks KMO in both lesioned and contralateral striatum, but does not interfere with KAT activity in either tissue |
|
1.14.13.9 | (6-chloro-1H-indazol-1-yl)acetic acid |
- |
|
1.14.13.9 | (6-chloro-5,7-dimethyl-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetic acid |
KMO-inhibitor 1 |
|
1.14.13.9 | (6-chloro-5,7-dimethyl-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetic acid |
- |
|
1.14.13.9 | (m-nitrobenzoyl)-alanine |
mNBA, leads to an increase of L-kynurenine and kynurenic acid concentrations in the brain cortex after application in vivo |
|
1.14.13.9 | (m-nitrobenzoyl)-alanine |
various pyrrolo[3,2-c]quinoline derivates cause enzyme inhibition |
|
1.14.13.9 | (m-nitrobenzoyl)-alanine |
50% inhibition at 0.9 micromolar |
|
1.14.13.9 | (R)-3-(5-chloro-2-oxo-6-(1-(pyridin-2-yl)ethoxy)benzo[d]oxazol-3(2H)-yl)propanoate |
- |
|
1.14.13.9 | (R,S)-2-amino-oxo-4-(3',4'-dichlorophenyl)butanoic acid |
FCE 28833, 50% inhibition at 0.2 microM, blocks not only the cerebral but also the peripheral enzyme |
|
1.14.13.9 | (R,S)-2-amino-oxo-4-(3'-4'-dichlorophenyl)butanoic acid |
- |
|